Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention: The Greek atorvastatin and coronary-heart-disease evaluation (GREACE) study

Current Medical Research and Opinion

Volumn 18, Issue 4, 2002, Pages 220-228

  Athyros, V G ^a   Papageorgiou, A A ^a   Mercouris, B R ^a   Athyrou, V V ^a   Symeonidis, A N ^a   Basayannis, E O ^a   Demitriadis, D S ^a   Kontopoulos, A G ^a  

^a NONE

Author keywords

'Usual' care; Atorvastatin; Coronary heart disease; Morbidity and mortality

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST OF ILLNESS; DIABETES MELLITUS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; HEALTH EDUCATION; HEALTH PROGRAM; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONEY; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; QUALITY ADJUSTED LIFE YEAR; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; ANALYSIS OF VARIANCE; BLOOD; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; GREECE; MIDDLE AGED; PROSPECTIVE STUDY; PUBLIC HEALTH; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; FEMALE; GREECE; HEPTANOIC ACIDS; HUMAN; LIPOPROTEINS, HDL CHOLESTEROL; LIPOPROTEINS, LDL CHOLESTEROL; LIPOPROTEINS, VLDL CHOLESTEROL; MALE; MIDDLE AGE; NATIONAL HEALTH PROGRAMS; PROSPECTIVE STUDIES; PYRROLES; TREATMENT OUTCOME; TRIGLYCERIDES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; HUMANS; MIDDLE AGED;

EID: 0036023515     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125000787     Document Type: Article

References (43)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
5. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
6. Aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE). Rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease
7. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE-II Euro Heart Survey Programme
8. The aggressive low density lipoprotein lowering controversy
9. HDL-cholesterol and the treatment of coronary heart disease: Contrasting effects of atorvastatin and simvastatin
10. Atorvastatin Comparative Cholesterol Efficacy and Safety (the ACCESS) Study. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels
11. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
12. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial
13. Relationship between LDL-C changes and CHD event reduction with pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS)
14. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
15. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
16. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
17. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double- blind trial
18. The Treatment of Coronary Heart Disease: Statins beyond cholesterol lowering
19. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion
20. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia
21. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels
22. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: A mechanism for reducing clinical events?
23. Improvement of nitric oxide dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation
24. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice
25. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells
26. 2+ release and vascular reactivity
27. Heart Rate Variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease
28. Prognostic value of reduction of heart rate variability after acute myocardial infarction: Clinical evaluation of a new analysis method
29. Heart rate variability as a means of assessing prognosis after acute myocardial infarction
30. Pulse pressure: A predictor of longterm cardiovascular mortality in a French male population
31. Large-artery elastic properties in young men. Relationships to serum lipoproteins and oxidized low-density lipoproteins
32. Effects of atorvastatin treatment on the oxidatively modified low density lipoprotein in hyperlipidemic patients
33. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
34. Pharmacoeconomics of lipid lowering agents for primary and secondary prevention of coronary artery disease
35. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases
36. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
37. Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial
38. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: Comparison between Belgium and the United States of a projected risk model
39. Cost-effectiveness of statins
40. Cost effectiveness of HMG-CoA reductase inhibition in Canada
41. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction